Premium
Ready When You Are: Easing Into Preemptive Pharmacogenetics
Author(s) -
He Y J,
McLeod H L
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.144
Subject(s) - clinical pharmacology , pharmacogenetics , context (archaeology) , medicine , pharmacology , clinical trial , adverse effect , intensive care medicine , psychology , biology , paleontology , biochemistry , genotype , gene
The promise of pharmacogenetics has included reduction of adverse drug events and enrichment for clinical efficacy. However, there has been very little assessment of the context in which this promise could be delivered. There are issues of return on effort and end points of meaningful impact that are crucial to moving this area of clinical pharmacology into practical benefit for our health system. Clinical Pharmacology & Therapeutics (2012); 92 4, 412–414. doi: 10.1038/clpt.2012.144